Foreign Corrupt Practices Act

With increased focus on the enforcement of anti-corruption laws in the United States and abroad, compliance with the U.S. Foreign Corrupt Practices Act (“FCPA”), the U.K. Bribery Act, and other anti-corruption regulations must be a priority for companies conducting business outside of the United States. Such companies, both large and small, regularly turn to Lewis Brisbois Bisgaard & Smith LLP attorneys for advice on these issues in the context of internal or government investigations conducted by both state and federal regulators. Our attorneys also work diligently on behalf of clients facing related civil enforcement actions.

Lewis Brisbois Bisgaard & Smith LLP is recognized as one of the leading law firms handling FCPA matters in the United States. Our lawyers have extensive knowledge and experience in all aspects of FCPA enforcement and compliance and have conducted numerous investigations, representing clients with a global presence before the Department of Justice, the Securities and Exchange Commission, the Colorado Attorney General’s Office, and various other regulators. Lewis Brisbois Bisgaard & Smith LLP also has the ability to advise clients in the development and implementation of FCPA compliance programs, including assessing clients’ risk of international bribery and/or corruption; creating and evaluating compliance policies, procedures, and other due diligence practices; and conducting training programs related to the FCPA and other anti-corruption regulations for clients worldwide.

Representative Matters

Conducted an internal investigation on behalf of one of the world’s leading investment firms whose foreign subsidiary allegedly violated the FCPA by bribing foreign government officials to secure business. Advised on issues related to self-reporting to regulators. Assisted with implementation of compliance policies.
Served as lead counsel for a multinational energy and manufacturing company investigated by domestic and foreign regulators for alleged liability resulting from involvement in bid-rigging and price-fixing worldwide.
Represented a top 10 pharmaceutical company in a multinational internal investigation, focusing on Latin America and Eastern Europe, to ascertain anti-corruption compliance weaknesses and recommend remedial measures and employee disciplinary actions. Advised on issues of self-reporting and compliance policy reform.